Hypothalamic rAAV-mediated GDNF gene delivery ameliorates age-related obesity

Nihal Tümer; Philip J. Scarpace; M. Devrim Dogan; Christopher S. Broxson; Michael Matheny; David M. Yurek; Carmen S. Peden; Corinna Burger; Nicholas Muzyczka; Ronald J. Mandel

doi:10.1016/j.neurobiolaging.2005.03.018

Hypothalamic rAAV-mediated GDNF gene delivery ameliorates age-related obesity

Nihal Tümer
, Philip J. Scarpace
, M. Devrim Dogan
, Christopher S. Broxson
, Michael Matheny
, David M. Yurek
, Carmen S. Peden
, Corinna Burger
, Nicholas Muzyczka
, Ronald J. Mandel

Producción científica: Article › revisión exhaustiva

25 Citas (Scopus)

Resumen

Intraventricular delivery of glial cell line-derived neurotrophic factor (GDNF) results in weight loss. We hypothesized that this effect of GDNF was likely mediated via its effects on dopaminergic neurons in the hypothalamus. Continuous rAAV-mediated GDNF expression in the hypothalamus of young and senescent rats resulted in weight loss compared to controls. However, GDNF-induced weight loss was unrelated to alterations in hypothalamic dopamine levels. The weight loss was associated with decreased food intake and increased energy expenditure, but these effects were not mediated by changes in hypothalamic NPY or POMC expression. Moreover, uncoupling protein 1 levels were unchanged in brown adipose tissue (BAT). The reduction in weight and adiposity were as great or greater in the aged rats even though aged rats are generally resistant to weight loss therapies. In summary, central GDNF gene delivery reduces weight and adiposity in young and aged rats through decreased food intake and increased energy expenditure. Our observations in aged rats suggest that GDNF may be especially effective in reducing obesity in aged obese rats.

Idioma original	English
Páginas (desde-hasta)	459-470
Número de páginas	12
Publicación	Neurobiology of Aging
Volumen	27
N.º	3
DOI	https://doi.org/10.1016/j.neurobiolaging.2005.03.018
Estado	Published - mar 2006

Nota bibliográfica

Funding Information:
This study was supported by the Medical Research Service of the Department of Veterans Affairs and NIH P01 NS 36302. The authors would like to thank Izzie Williams for expert histological assistance. Nicholas Muzyczka is an inventor on patents related to recombinant AAV Technology and owns equity in a gene therapy company that is commercialising AAV for gene therapy applications.

Financiación

This study was supported by the Medical Research Service of the Department of Veterans Affairs and NIH P01 NS 36302. The authors would like to thank Izzie Williams for expert histological assistance. Nicholas Muzyczka is an inventor on patents related to recombinant AAV Technology and owns equity in a gene therapy company that is commercialising AAV for gene therapy applications.

Financiadores	Número del financiador
National Institutes of Health (NIH)
Institute of Neurological Disorders and Stroke National Advisory Neurological Disorders and Stroke Council	P01NS036302
Institute of Neurological Disorders and Stroke National Advisory Neurological Disorders and Stroke Council
U.S. Department of Veterans Affairs

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Good health and well being

ASJC Scopus subject areas

General Neuroscience
Aging
Clinical Neurology
Developmental Biology
Geriatrics and Gerontology

Acceder al documento

10.1016/j.neurobiolaging.2005.03.018

Otros archivos y enlaces

Citar esto

@article{ed1e8acb2f8940dea8b46c909d030166,

title = "Hypothalamic rAAV-mediated GDNF gene delivery ameliorates age-related obesity",

abstract = "Intraventricular delivery of glial cell line-derived neurotrophic factor (GDNF) results in weight loss. We hypothesized that this effect of GDNF was likely mediated via its effects on dopaminergic neurons in the hypothalamus. Continuous rAAV-mediated GDNF expression in the hypothalamus of young and senescent rats resulted in weight loss compared to controls. However, GDNF-induced weight loss was unrelated to alterations in hypothalamic dopamine levels. The weight loss was associated with decreased food intake and increased energy expenditure, but these effects were not mediated by changes in hypothalamic NPY or POMC expression. Moreover, uncoupling protein 1 levels were unchanged in brown adipose tissue (BAT). The reduction in weight and adiposity were as great or greater in the aged rats even though aged rats are generally resistant to weight loss therapies. In summary, central GDNF gene delivery reduces weight and adiposity in young and aged rats through decreased food intake and increased energy expenditure. Our observations in aged rats suggest that GDNF may be especially effective in reducing obesity in aged obese rats.",

keywords = "Aging, GDNF, Gene delivery, Hypothalamus, Obesity",

author = "Nihal T{\"u}mer and Scarpace, \{Philip J.\} and Dogan, \{M. Devrim\} and Broxson, \{Christopher S.\} and Michael Matheny and Yurek, \{David M.\} and Peden, \{Carmen S.\} and Corinna Burger and Nicholas Muzyczka and Mandel, \{Ronald J.\}",

note = "Funding Information: This study was supported by the Medical Research Service of the Department of Veterans Affairs and NIH P01 NS 36302. The authors would like to thank Izzie Williams for expert histological assistance. Nicholas Muzyczka is an inventor on patents related to recombinant AAV Technology and owns equity in a gene therapy company that is commercialising AAV for gene therapy applications.",

year = "2006",

month = mar,

doi = "10.1016/j.neurobiolaging.2005.03.018",

language = "English",

volume = "27",

pages = "459--470",

number = "3",

}

TY - JOUR

T1 - Hypothalamic rAAV-mediated GDNF gene delivery ameliorates age-related obesity

AU - Tümer, Nihal

AU - Scarpace, Philip J.

AU - Dogan, M. Devrim

AU - Broxson, Christopher S.

AU - Matheny, Michael

AU - Yurek, David M.

AU - Peden, Carmen S.

AU - Burger, Corinna

AU - Muzyczka, Nicholas

AU - Mandel, Ronald J.

N1 - Funding Information: This study was supported by the Medical Research Service of the Department of Veterans Affairs and NIH P01 NS 36302. The authors would like to thank Izzie Williams for expert histological assistance. Nicholas Muzyczka is an inventor on patents related to recombinant AAV Technology and owns equity in a gene therapy company that is commercialising AAV for gene therapy applications.

PY - 2006/3

Y1 - 2006/3

N2 - Intraventricular delivery of glial cell line-derived neurotrophic factor (GDNF) results in weight loss. We hypothesized that this effect of GDNF was likely mediated via its effects on dopaminergic neurons in the hypothalamus. Continuous rAAV-mediated GDNF expression in the hypothalamus of young and senescent rats resulted in weight loss compared to controls. However, GDNF-induced weight loss was unrelated to alterations in hypothalamic dopamine levels. The weight loss was associated with decreased food intake and increased energy expenditure, but these effects were not mediated by changes in hypothalamic NPY or POMC expression. Moreover, uncoupling protein 1 levels were unchanged in brown adipose tissue (BAT). The reduction in weight and adiposity were as great or greater in the aged rats even though aged rats are generally resistant to weight loss therapies. In summary, central GDNF gene delivery reduces weight and adiposity in young and aged rats through decreased food intake and increased energy expenditure. Our observations in aged rats suggest that GDNF may be especially effective in reducing obesity in aged obese rats.

AB - Intraventricular delivery of glial cell line-derived neurotrophic factor (GDNF) results in weight loss. We hypothesized that this effect of GDNF was likely mediated via its effects on dopaminergic neurons in the hypothalamus. Continuous rAAV-mediated GDNF expression in the hypothalamus of young and senescent rats resulted in weight loss compared to controls. However, GDNF-induced weight loss was unrelated to alterations in hypothalamic dopamine levels. The weight loss was associated with decreased food intake and increased energy expenditure, but these effects were not mediated by changes in hypothalamic NPY or POMC expression. Moreover, uncoupling protein 1 levels were unchanged in brown adipose tissue (BAT). The reduction in weight and adiposity were as great or greater in the aged rats even though aged rats are generally resistant to weight loss therapies. In summary, central GDNF gene delivery reduces weight and adiposity in young and aged rats through decreased food intake and increased energy expenditure. Our observations in aged rats suggest that GDNF may be especially effective in reducing obesity in aged obese rats.

KW - Aging

KW - GDNF

KW - Gene delivery

KW - Hypothalamus

KW - Obesity

UR - https://www.scopus.com/pages/publications/31844445994

UR - https://www.scopus.com/pages/publications/31844445994#tab=citedBy

U2 - 10.1016/j.neurobiolaging.2005.03.018

DO - 10.1016/j.neurobiolaging.2005.03.018

M3 - Article

C2 - 15964099

AN - SCOPUS:31844445994

SN - 0197-4580

VL - 27

SP - 459

EP - 470

JO - Neurobiology of Aging

JF - Neurobiology of Aging

IS - 3

ER -

Hypothalamic rAAV-mediated GDNF gene delivery ameliorates age-related obesity

Resumen

Nota bibliográfica

Financiación

ODS de las Naciones Unidas

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto